Genetic strategies for antibacterial drug discovery

Nature Reviews Genetics

Volumn 4, Issue 6, 2003, Pages 442-456

  Miesel, Lynn ^a   Greene, Jonathan ^a   Black, Todd A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE; AMINO ACID TRANSFER RNA LIGASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ARABINOSE; BACTERIAL DNA; BACTERICIDE; BETA LACTAM; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ELONGATION FACTOR G; FUCOSE; GLYCOPEPTIDE; INITIATION FACTOR 1; LACTOSE; MACROLIDE; MESSENGER RNA; METICILLIN; OXAZOLIDINONE DERIVATIVE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RHAMNOSE; RNA POLYMERASE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN; XYLOSE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENETICS; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM MUTANT; CELL ASSAY; DNA SEQUENCE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE INSERTION; GENE SEQUENCE; GENETIC PROCEDURES; GENETIC SCREENING; GENOME ANALYSIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MEDICAL TECHNOLOGY; MYCOBACTERIUM; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SEQUENCE ANALYSIS; TECHNIQUE; TRANSPOSON;

ANTI-BACTERIAL AGENTS; BIOLOGICAL ASSAY; DNA, RECOMBINANT; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; GENETIC SCREENING; GENOME, BACTERIAL; GENOMICS; MUTAGENESIS;

BACTERIA (MICROORGANISMS); INSERTION SEQUENCES; MYCOBACTERIUM; NEGIBACTERIA; POSIBACTERIA; TRANSPOSONS;

EID: 0038779197     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1086     Document Type: Review

References (161)

1. Fleischmann, R. D. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496-512 (1995).
2. Hiramatsu, K. et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135-136 (1997).
3. Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. Science 277, 1453-1474 (1997).
4. Kunst, F. et al. The complete genome sequence of the Gram-positive bacterium Bacillus subtilis. Nature 390, 249-256 (1997).
5. Goffeau, A. et al. Life with 6000 genes. Science 274, 546, 563-567 (1996).
6. Breithaupt, H. The new antibiotics. Nature Biotechnol. 17, 1165-1169 (1999).
7. Lederberg, J. Infectious history. Science 288, 287-293 (2000).
8. Davies, J. Inactivation of antibiotics and the dissemination of resistance genes. Science 264, 375-382 (1994).
9. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775-781 (2000).
10. Imada, A. & Hotta, K. in Emerging Targets in Antibacterial and Antifungal Chemotherapy (eds Sutcliffe, J. A. & Georgopapadakou, N. H.) 1-23 (Champman and Hall, New York, 1992).
11. Gootz, T. D. Discovery and development of new antimicrobial agents. Clin. Microbiol. Rev. 3, 13-31 (1990). References 10 and 11 review the approaches for finding antimicrobials before the insurgence of genomics-based strategies. The challenges to the identification of antimicrobial compounds from microbial fermentation broths are discussed.
12. McDevitt, D. & Rosenberg, M. Exploiting genomics to discover new antibiotics. Trends Microbiol. 9, 611-617 (2001).
13. Hackbarth, C. J. et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46, 2752-2764 (2002).
14. Payne, D. J. et al. Discovery of a novel and potent class of Fabl-directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118-3124 (2002). References 13 and 14 describe the development of antibacterial compounds from enzyme inhibitors that had little initial antibacterial activity.
15. Parra, G., Blanco, E. & Guigo, R. GenelD in Drosophila. Genome Res. 10, 511-515 (2000).
16. Borodovsky, M. & McIninch, J. Recognition of genes in DNA sequence with ambiguities. Biosystems 30, 161-171 (1993).
17. Burge, C. & Karlin, S. Prediction of complete gene structures in human genomic DNA. J. Mol. Biol. 268, 78-94 (1997).
18. Xu, Y. & Uberbacher, E. C. Automated gene identification in large-scale genomic sequences. J. Comput. Biol. 4, 325-338 (1997).
19. Delcher, A. L., Harmon, D., Kasif, S., White, O. & Salzberg, S. L. Improved microbial gene identification with GLIMMER. Nucleic Acids Res. 27, 4636-4641 (1999).
20. Wheeler, D. L. et al. Database resources of the National Center for Biotechnology. Nucl. Acids Res. 31, 28-33 (2003).
21. Rudd, K. E. EcoGene: a genome sequence database for Escherichia coli K-12. Nucleic Acids Res. 28, 60-64 (2000).
22. Moszer, I., Jones, L. M., Moreira, S., Fabry, C. & Danchin, A. SubtiList: the reference database for the Bacillus subtilis genome. Nucleic Acids Res 30, 62-65 (2002).
23. Cole, S. T. Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS Lett. 452, 7-10 (1999).
24. Altschul, S. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl. Acids Res. 25, 3389-3402 (1997).
25. Tatusov, R. L. et al. The COG database: new developments in phylogenetic classification of proteins from complete genomes. Nucl. Acids Res. 29, 22-28 (2001).
26. Schmid, M. B. Structural proteomics: the potential of high-throughput structure determination. Trends Microbiol. 10, 27-31 (2002).
27. Marti-Renom, M. A. et al. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29, 291-325 (2000).
28. Rupp, B. High-throughput crystallography at an affordable cost: the TB structural genomics consortium crystallization facility. Acc. Chem. Res. 36, 173-181 (2003).
29. Mushegian, A. R. & Koonin, E. V. A minimal gene set for cellular life derived by comparison of complete bacterial genomes. Proc. Natl Acad. Sci. USA 93, 10268-10273 (1996).
30. Koonin, E. V. How many genes can make a cell: the minimal-gene-set concept. Annu. Rev. Genom. Hum. Genet. 1, 99-116 (2000).
31. Hutchison, C. A. et al. Global transposon mutagenesis and a minimal Mycoplasma genome. Science 286, 2165-2169 (1999).
32. Arigoni, F. et al. A genome-based approach for the identification of essential bacterial genes. Nature Biotechnol. 16, 851-856 (1998). This manuscript heralded the fact that conserved genes are not necessarily essential. Furthermore, some genes that are essential for one organism can be dispensable for another (see also references 33-36).
33. Gerdes, S. Y. et al. From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J. Bacteriol. 184, 4555-4572 (2002). This article shows an example of the identification of conserved biochemical pathways using bioinformatics and genetic footprinting to distinguish essential enzymes of the pathways.
34. Washburn, R. S., Marra, A., Bryant, A. P., Rosenberg, M. & Gentry, D. R. rho is not essential for viability or virulence in Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 1099-1103 (2001).
35. Minkovsky, N. et al. Bex, the Bacillus subtilis homolog of the essential Escherichia coli GTPase Era, is required for normal cell division and spore formation. J. Bacteriol. 184, 6389-6394 (2002).
36. Heath, R. J. & Rock, C. O. A triclosan-resistant bacterial enzyme. Nature 406, 145-146 (2000).
37. Chalker, A. F. & Lunsford, R. D. Rational identification of new antibacterial drug targets that are essential for viability using a genomics-based approach. Pharmacol. Ther. 95, 1-20 (2002). This review provides comprehensive descriptions of the many methods for the identification of essential genes in bacteria.
38. Hare, R. S. et al. Genetic footprinting in bacteria. J. Bacteriol. 183, 1694-1706 (2001).
39. Akerley, B. J. et al. Systematic identification of essential genes by in vitro mariner mutagenesis. Proc. Natl Acad. Sci. USA 95, 8927-8932 (1998).
40. Badarinarayana, V. et al. Selection analyses of insertional mutants using subgenic-resolution arrays. Nature Biotechnol. 19, 1060-1065 (2001).
41. Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Comprehensive identification of conditionally essential genes in mycobacteria. Proc. Natl Acad. Sci. USA 98, 12712-12717 (2001).
42. Akerley, B. J. et al. A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc. Natl Acad. Sci. USA 99, 966-971 (2002).
43. Wong, S. M. & Mekalanos, J. J. Genetic footprinting with mariner-based transposition in Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 97, 10191-10196 (2000).
44. Lee, M. S., Dougherty, B. A., Madeo, A. C. & Morrison, D. A. Construction and analysis of a library for random insertional mutagenesis in Streptococcus pneumoniae: use for recovery of mutants defective in genetic transformation and for identification of essential genes. Appl. Environ. Microbiol. 65, 1883-1890 (1999).
45. Vagner, V., Dervyn, E. & Ehrlich, S. A vector for systematic gene inactivation in Bacillus subtilis. Microbiology 144, 3097-3104 (1998).
46. Kobayashi, K. et al. Essential Bacillus subtilis genes. Proc. Natl Acad. Sci. USA 100, 4678-4683 (2003). This landmark paper describes target-directed disruptions of ∼3,000 B. subtilis genes. Online tables list the essential genes in Bacillus, and their cellular functions in essential biochemical pathways are depicted in online figures. This complete analysis provides a crucial comparison for all other target validation efforts.
47. Thanassi, J. A., Hartman-Neumann, S. L., Dougherty, T. J., Dougherty, B. A. & Pucci, M. J. Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. Nucleic Acids Res. 30, 3152-3162 (2002).
48. Anderson, P. & Roth, J. Spontaneous tandem genetic duplications in Salmonella typhimurium arise by unequal recombination between rRNA (rrn) cistrons. Proc. Natl Acad. Sci. USA 78, 3113-3117 (1981).
49. Schmid, M. B., Kapur, N., Isaacson, D. R., Lindroos, P. & Sharpe, C. Genetic analysis of temperature-sensitive lethal mutants of Salmonella typhimurium. Genetics 123, 625-633 (1989).
50. Sun, D. et al. in 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 77 (American Society for Microbiology, Chicago, 2001).
51. Pestka, S., Daugherty, B. L., Jung, V., Hotta, K. & Pestka, R. K. Anti-mRNA: specific inhibition of translation of single mRNA molecules. Proc. Natl Acad. Sci. USA 81, 7525-7528 (1984).
52. Kernodle, D., Voladri, R., Menzies, B., Hager, C. & Edwards, K. Expression of an antisense hla fragment in Staphylococcus aureus reduces α-toxin production in vitro and attenuates lethal activity in a murine model. Infect. Immun. 65, 179-184 (1997).
53. Parish, T. & Stoker, N. G. Development and use of a conditional antisense mutagenesis system in mycobacteria. FEMS Microbiol. Lett. 154, 151-157 (1997).
54. Wilson, T., de Lisle, G., Marcinkeviciene, J., Blanchard, J. & Collins, D. Antisense RNA to ahpC, an oxidative stress defence gene involved in isoniazid resistance, indicates that AhpC of Mycobacterium bovis has virulence properties. Microbiology 144, 2687-2695 (1998).
55. Greendyke, R., Rajagopalan, M., Parish, T. & Madiraju, M. V. V. S. Conditional expression of Mycobacterium smegmatis dnaA, an essential DNA replication gene. Microbiology 148, 3887-3900 (2002). This study used antisense RNA and an inducible promoter to construct conditionally defective strains of Mycobacterium smegmatis. Along with references 77, 78 and 82, this provides the tools for characterizing essential genes in mycobacteria.
56. Ji, Y. et al. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293, 2266-2269 (2001).
57. Forsyth, R. A. et al. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43, 1387-1400 (2002). This paper describes a comprehensive analysis of the S. aureus genome by the conditional inactivation of genes with antisense RNA. It also describes the use of antisense-bearing strains to identify the cellular targets of antimicrobials.
58. Jain, C., Deana, A. & Belasco, J. G. Consequences of RNase E scarcity in Escherichia coli. Mol. Microbiol. 43, 1053-1064 (2002).
59. Guzman, L. M., Belin, D., Carson, M. J. & Beckwith, J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J. Bacteriol. 177, 4121-4130 (1995).
60. Haldimann, A., Daniels, L. L. & Wanner, B. L. Use of new methods for construction of tightly regulated arabinose and rhamnose promoter fusions in studies of the Escherichia coli phosphate regulon. J. Bacteriol. 180, 1277-1286 (1998).
61. Chow, W. Y. & Berg, D. E. Tn5tac1, a derivative of transposon Tn5 that generates conditional mutations. Proc. Natl Acad. Sci. USA 85, 6468-6472 (1988).
62. Rappleye, C. A. & Roth, J. R. A Tn10 derivative (T-POP) for isolation of insertions with conditional (tetracycline-dependent) phenotypes. J. Bacteriol. 179, 5827-5834 (1997).
63. de Lorenzo, V., Eltis, L., Kessler, B. & Timmis, K. N. Analysis of Pseudomonas gene products using laclq/Ptrp-lac plasmids and transposons that confer conditional phenotypes. Gene 123, 17-24 (1993).
64. Geissendorfer, M. & Hillen, W. Regulated expression of heterologous genes in Bacillus subtilis using the Tn10 encoded tet regulatory elements. Appl. Microbiol. Biotechnol. 33, 657-663 (1990).
65. Dervyn, E. et al. Two essential DNA polymerases at the bacterial replication fork. Science 294, 1716-1719 (2001).
66. Fan, F. et al. Regulated ectopic expression and allelic-replacement mutagenesis as a method for gene essentiality testing in Staphylococcus aureus. Plasmid 46, 71-75 (2001).
67. Jana, M., Luong, T. T., Komatsuzawa, H., Shigeta, M. & Lee, C. Y. A method for demonstrating gene essentiality in Staphylococcus aureus. Plasmid 44, 100-104 (2000).
68. Stieger, M., Wohlgensinger, B., Kamber, M., Lutz, R. & Keck, W. Integrational plasmids for the tetracycline-regulated expression of genes in Streptococcus pneumoniae. Gene 226, 243-251 (1999).
69. Apfel, C. M., Takacs, B., Fountoulakis, M., Stieger, M. & Keck, W. Use of genomics to identify bacterial undecaprenyl pyrophosphate synthetase: cloning, expression, and characterization of the essential uppS gene. J. Bacteriol. 181, 483-492 (1999). This paper describes the use of genomic sequences in combination with proteomics approaches to identify putative targets and initiate functional studies.
70. Chan, P. F. et al. Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae. J. Bacteriol. 185, 2051-2058 (2003).
71. Judson, N. & Mekalanos, J. J. TnAraOut, a transposon-based approach to identify and characterize essential bacterial genes. Nature Biotechnol. 18, 740-745 (2000).
72. Hoang, T. T., Karkhoff-Schweizer, R. R., Kutchma, A. J. & Schweizer, H. P. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212, 77-86 (1998).
73. Link, A., Phillips, D. & Church, G. Methods for generating precise deletions and insertions in the genome of wild-type Escherichia coli: application to open reading frame characterization. J. Bacteriol. 179, 6228-6237 (1997).
74. Fabret, C., Ehrlich, S. D. & Noirot, P. A new mutation delivery system for genome-scale approaches in Bacillus subtilis. Mol. Microbiol. 46, 25-36 (2002).
75. Lau, P. C. Y., Sung, C. K., Lee, J. H., Morrison, D. A. & Cvitkovitch, D. G. PCR ligation mutagenesis in transformable streptococci: application and efficiency. J. Microbiol. Methods 49, 193-205 (2002).
76. Xia, M., Lunsford, R. D., McDevitt, D. & Lordanescu, S. Rapid method for the identification of essential genes in Staphylococcus aureus. Plasmid 42, 144-149 (1999).
77. Bardarov, S. et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148, 3007-3017 (2002).
78. Pavelka, M. S. & Jacobs, W. R. Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guerin, and Mycobacterium tuberculosis H37Rv by allelic exchange. J. Bacteriol. 181, 4780-4789 (1999).
79. Hoang, T. T., Kutchma, A. J., Becher, A. & Schweizer, H. P. Integration-proficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains. Plasmid 43, 59-72 (2000).
80. Haldimann, A. & Wanner, B. L. Conditional-replication, integration, excision, and retrieval plasmid-host systems for gene structure-function studies of bacteria. J. Bacteriol. 183, 6384-6393 (2001).
81. Guerout-Fleury, A. M., Frandsen, N. & Stragier, P. Plasmids for ectopic integration in Bacillus subtilis. Gene 180, 57-61 (1996).
82. Braunstein, M., Bardarov, S. S. & Jacobs, W. R. Genetic methods for deciphering virulence determinants of Mycobacterium tuberculosis. Methods Enzymol. 358, 67-99 (2002).
83. Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl Acad. Sci. USA 97, 6640-6645 (2000).
84. Lehman, I. R. DNA ligase: structure, mechanism, and function. Science 186, 790-797 (1974).
85. Kanehara, K., Akiyama, Y. & Ito, K. Characterization of the yaeL gene product and its S2P-protease motifs in Escherichia coli. Gene 281, 71-79 (2001). The conditional inactivation of yaeL causes a rapid bactericidal effect. Unfortunately, it is not an ideal target, as null mutations in another gene bypass the requirement for this gene (see reference 97).
86. Campbell, T. L. & Brown, E. D. Characterization of the depletion of 2-C-methyl-D-erythritol-2,4-cyclodiphosphate synthase in Escherichia coli and Bacillus subtilis. J. Bacteriol. 184, 5609-5618 (2002).
87. McCoy, A. J., Sandlin, R. C. & Maurelli, A. T. In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance. J. Bacteriol. 185, 1218-1228 (2003). References 87 and 88 provide superb examples of validating targets with conditional mutants and antimicrobial compounds. Conditional mutants of murA and inhA cause bactericidal effects, such as the antimicrobial compounds that target these functions - fosfomycin (reference 101) and isoniazid (reference 102).
88. Vilcheze, C. et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 182, 4059-4067 (2000).
89. Kobayashi, G., Moriya, S. & Wada C. Deficiency of essential GTP-binding protein ObgE in Escherichia coli inhibits chromosome partition. Mol. Microbiol. 41, 1037-1051 (2001).
90. Carson, M. J., Barondess, J. & Beckwith, J. The FtsQ protein of Escherichia coli: membrane topology, abundance, and cell division phenotypes due to overproduction and insertion mutations. J. Bacteriol. 173, 2187-2195 (1991).
91. Turnowsky, F., Fuchs, K., Jeschek, C. & Hogenauer, G. envM genes of Salmonella typhimurium and Escherichia coli. J. Bacteriol. 171, 6555-6565 (1989).
92. McNicholas, P. M. et al. Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. 44, 1121-1126 (2000).
93. Egan, A. F. & Russell, R. R. Conditional mutations affecting the cell envelope of Escherichia coli K-12. Genet. Res. 21, 139-152 (1973).
94. Martin, P. K., Li, T., Sun, D., Biek, D. P. & Schmid, M. B. Role in cell permeability of an essential two-component system in Staphylococcus aureus. J. Bacteriol. 181, 3666-3673 (1999).
95. Bochner, B. R., Gadzinski, P. & Panomitros, E. Phenotype microarrays for high-throughput phenotypic testing and assay of gene function. Genome Res. 11, 1246-1255 (2001).
96. Murphy, C. K., Stewart, E. J. & Beckwith, J. A double counter-selection system for the study of null alleles of essential genes in Escherichia coli. Gene 155, 1-7 (1995).
97. Alba, B. M., Leeds, J. A., Onufryk, C., Lu, C. Z. & Gross, C. A. DegS and YaeL participate sequentially in the cleavage of RseA to activate the σ-E-dependent extracytoplasmic stress response. Genes Dev. 16, 2156-2168 (2002).
98. Apfel, C. M. et al. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 45, 1058-1064 (2001).
99. Margolis, P. S. et al. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. 44, 1825-1831 (2000). References 98 and 99 describe spontaneous resistance to deformylase inhibitors that occurs by null mutations that bypass the requirement for deformylase. See references 139-140 for a more positive view of the deformylase target.
100. Schmid, M. B. in Antibiotic Development and Resistance. (eds Hughes, D. & Andersson, D. I.) 197-208 (Taylor and Francis, New York, 2001).
101. Marquardt, J. L., Siegele, D. A., Kolter, R. & Walsh, C. T. Cloning and sequencing of Escherichia coli murZ and purification of its product, a UDP-N-acetylglucosamine enolpyruvyl transferase. J. Bacteriol. 174, 5748-5722 (1992).
102. Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227-230 (1994).
103. Tokunaga, M., Loranger, J. M. & Wu, H. Isolation and characterization of an Escherichia coli clone overproducing prolipoprotein signal peptidase. J. Biol. Chem. 258, 12102-12105 (1983).
104. Zhang, L. et al. Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene 255, 297-305 (2000).
105. Chen, D. Z. et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39, 1256-1262 (2000).
106. DeVito, J. A. et al. An array of target-specific screening strains for antibacterial discovery. Nature Biotechnol. 20, 478-483 (2002). This paper describes the use of conditionally defective strains to identify new target-directed antimicrobials.
107. Heath, R. J. et al. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 274, 11110-11114 (1999).
108. Van der Meide, P. H. et al. Molecular properties of two mutant species of the elongation factor Tu. Eur. J. Biochem. 117, 1-6 (1981).
109. Haselbeck, R. J. et al. in Comprehensive essential gene identification as a platform for novel anti-infective drug discovery. Curr. Pharm. Des. 8, 1155-1172 (2002).
110. Neidhardt, F. C. & Savageau, M. A. Regulation Beyond the Operon (eds Neidhardt, F. C. et al.) (ASM, Washington D.C., 1996).
111. Bechor, O., Smulski, D. R., Van Dyk, T. K., LaRossa, R. A. & Belkin, S. Recombinant microorganisms as environmental biosensors: pollutants detection by Escherichia coli bearing fabA'::lux fusions. J. Biotechnol. 94, 125-132 (2002).
112. Hughes, K. T., Olivera, B. M. & Roth, J. R. Structural gene for NAD synthetase in Salmonella typhimurium. J. Bacteriol. 170, 2113-2120 (1988).
113. Sun, D., Cohen, S., Mani, N., Murphy, C. & Rothstein, D. M. A pathway-specific cell based screening system to detect bacterial cell wall inhibitors. J. Antibiot. 55, 279-287 (2002). This paper shows how a thorough understanding of a gene-regulation pathway can be used to design a clever assay that provides a robust screen for inhibitors of cell-wall biosynthesis.
114. Uehara, T. & Park, J. T. Role of the murein precursor UDP-N-acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid-D-Ala-D-Ala in repression of β-lactamase induction in cell division mutants. J. Bacteriol. 184, 4233-4239 (2002).
115. DeCenzo, M. et al. Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria. J. Antibiot. 55, 288-295 (2002).
116. Van Dyk, T. K., Ayers, B. L., Morgan, R. W. & Larossa, R. A. Constricted flux through the branched-chain amino acid biosynthetic enzyme acetolactate synthase triggers elevated expression of genes regulated by rpoS and internal acidification. J. Bacteriol. 180, 785-792 (1998). This manuscript shows how gene fusions can be used to characterize the cellular consequences of inhibiting a particular enzyme. This might provide a powerful screening strategy to identify new antimicrobial compounds.
117. Cao, M., Wang, T., Ye, R. & Helmann, J. D. Antibiotics that inhibit cell wall biosynthesis induce expression of the Bacillus subtilis σ(W) and σ(M) regulons. Mol. Microbiol. 45, 1267-1276 (2002).
118. Youngman, P., Tepper, R. & Moore, J. in Current Clinical Topics in Infectious Diseases (eds Remington, J. & Swartz, M.) 366-390 (Blackwell Sciences, Malden, Massachusetts, 1999).
119. Van Dyk, T. K. et al. A genomic approach to gene fusion technology. Proc. Natl Acad. Sci. USA 98, 2555-2560 (2001).
120. Rhodius, V., Van Dyk, T. K., Gross, C. & LaRossa, R. A. Impact of genomic technologies on studies of bacterial gene expression. Annu. Rev. Microbiol. 56, 599-624 (2002).
121. Morrow, B. J. & Shaw, K. J. in Pathogen Genomics (ed. Shaw, K. J.) 97-112 (Humana, Totowa, New Jersey, 2002).
122. Youngman, P. in Bacterial Resistance to Antimicrobials: Mechanisms, Genetics, Medical Practice and Public Health. (eds Lewis, K., Salyers, A., Taber, H. & Wax, R.) (Dekker, New York, 2002).
123. Rosamond, J. & Allsop, A. Harnessing the power of the genome in the search for new antibiotics. Science 287, 1973-1976 (2000).
124. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863-14868 (1998).
125. Marton, M. J. et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Med. 4, 1293-1301 (1998).
126. Ng, W. L., Kazmierczak, K. M., Robertson, G. T., Gilmour, R. & Winkler, M. E. Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors. J. Bacteriol. 185, 359-370 (2003). This investigation used expression arrays to identify changes in gene-expression patterns that are caused by certain antibiotic classes. The findings indicate a possible strategy for identifying new translation inhibitors.
127. Gmuender, H. et al. Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. Genome Res. 11, 28-42 (2001).
128. Wilson, M. et al. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl Acad. Sci. USA 96, 12833-12838 (1999).
129. Belanger, A. E., Lai, A., Brackman, M. A. & LeBlanc, D. J. PCR-based ordered genomic libraries: a new approach to drug target identification for Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46, 2507-2512 (2002). This report describes a rapid method to identify resistance genes and discover the cellular targets of antimicrobial compounds. This provides a means to characterize antimicrobial compounds without bias to preselected targets. This method might also work in naturally competent bacteria other than S. pneumonieae.
130. Projan, S. J. & Youngman, P. J. Antimicrobials: new solutions badly needed. Curr. Opin. Microbiol. 5, 463-465 (2002). This article describes a disturbing trend: many drug companies are abandoning their commitment to antibacterial drug discovery. Factors contributing to this trend are discussed, and include limitations to the target-directed strategies that have been the basis for most recent discovery efforts.
131. Li, Q., Mitscher, L. A. & Shen, L. L. The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med. Res. Rev. 20, 231-293 (2000).
132. Moellering, R. C. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138, 135-142 (2003).
133. Levy, S. B. Active efflux, a common mechanism for biocide and antibiotic resistance. J. Appl. Microbiol. 92 (Suppl.) 65-71 (2002).
134. Bearden, D. T. & Danziger, L. H. Mechanism of action of and resistance to quinolones. Pharmacotherapy 21, 224-232 (2001).
135. Wilson, P. et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51, 186-188 (2003).
136. Haney, S. A., Alksne, L. E., Dunman, P. M., Murphy, E. & Projan, S. J. Genomics in anti-infective drug discovery - getting to endgame. Curr. Pharm. Des. 8, 1099-1118 (2002).
137. Projan, S. J. New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr. Opin. Pharmacol. 2, 513-522 (2002).
138. Yuan, Z., Trias, J. & White, R. J. Deformylase as a novel antibacterial target. Drug Discov. Today 6, 954-961 (2001).
139. Waller, A. S. & Clements, J. M. Novel approaches to antimicrobial therapy: peptide deformylase. Curr. Opin. Drug Discov. Devel. 5, 785-792 (2002). References 138 and 139 review the first genomically-derived target that yielded an antimicrobial drug candidate. The optimism expressed in these papers contrasts with the view expressed in reference 98.
140. Clements, J. M. et al. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 45, 563-570 (2001).
141. Margolis, P. et al. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. 45, 2432-2435 (2001).
142. Heath, R. J., White, S. W. & Rock, C. O. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58, 695-703 (2002).
143. Payne, D. J., Warren, P. V., Holmes, D. J., Ji, Y. & Lonsdale, J. T. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov. Today 6, 537-544 (2001).
144. Joswick, H. L., Corner, T. R., Silvernale, J. N. & Gerhardt, P. Antimicrobial actions of hexachlorophene: release of cytoplasmic materials. J. Bacteriol. 108, 492-500 (1971).
145. Silvernale, J. N., Joswick, H. L., Corner, T. R. & Gerhardt, P. Antimicrobial actions of hexachlorophene: cytological manifestations. J. Bacteriol. 108, 482-491 (1971).
146. McMurry, L. M., Oethinger, M. & Levy, S. B. Triclosan targets lipid synthesis. Nature 394, 531-532 (1998).
147. Heath, R. J., Yu, Y.-T., Shapiro, M. A., Olson, E. & Rock, C. O. Broad spectrum antimicrobial biocides target the Fabl component of fatty acid synthesis. J. Biol. Chem. 273, 30316-30320 (1998).
148. Miller, W. H. et al. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (Fabl). J. Med. Chem. 45, 3246-3256 (2002).
149. Hoang, T. T. & Schweizer, H. P. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (Fabl): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis. J. Bacteriol. 181, 5489-5497 (1999). References 149 and 150 predict that the differential essentiality of certain genes among different microbes could hamper the pursuit of certain targets. The fabl-encoded enoyl-ACP reductase is essential in many Gram-negatives and -positives, but is dispensable in B. subtilis and Pseudomonas aeruginosa. These organisms have a second enoyl reductase, FabK, that renders them resistant to Fabl-directed compounds such as triclosan. This finding did not stop the development of Fabl inhibitors by other investigators (references 14, 143 and 148).
150. Heath, R. J., Su, N., Murphy, C. K. & Rock, C. O. The enoyl-[acyl-carrier-protein] reductases Fabl and FabL from Bacillus subtilis. J. Biol. Chem. 275, 40128-40133 (2000).
151. Kuroda, M. et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357, 1225-1240 (2001).
152. Ferretti, J. J. et al. Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc. Natl Acad. Sci. USA 98, 4658-4663 (2001).
153. Tettelin, H. et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293, 498-506 (2001).
154. Paulsen, I. T. et al. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299, 2071-2074 (2003).
155. Himmelreich, R. et al. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucl. Acids Res. 24, 4420-4449 (1996).
156. Stover, C. K. et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959-964 (2000).
157. Tomb, J. F. et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388, 539-547 (1997).
158. Parkhill, J. et al. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 413, 848-852 (2001).
159. McClelland, M. et al. Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature 413, 852-856 (2001).
160. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
161. Vaughan, M. D., Sampson, P. D. & Hanek, J. F. Methionine in and out of proteins: targets for drug design. Curr. Med. Chem. 9, 385-409 (2003).